[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Wiedmann MW, Mössner J: Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. Curr Drug Targets; 2010 Jul;11(7):834-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma of the biliary tree are rare tumors of the gastrointestinal tract with worldwide rising incidence for intrahepatic cholangiocarcinoma during the last years.
  • Non-resectable biliary tract cancer is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Biliary Tract Neoplasms / drug therapy. Clinical Trials as Topic. Drug Delivery Systems / methods. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / pharmacology. Signal Transduction / drug effects
  • [MeSH-minor] Drug Screening Assays, Antitumor / methods. Humans. Models, Biological. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors


2. Dingle BH, Rumble RB, Brouwers MC, Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group: The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol; 2005 Dec;19(12):711-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review.
  • BACKGROUND: Cholangiocarcinoma and gallbladder cancer are difficult to treat curatively.
  • The treatment of choice is surgery, dependent on detection at a resectable stage.
  • Considering the lack of treatment options for cholangiocarcinoma and gallbladder cancer, a systematic review of the evidence on gemcitabine use for these indications was performed.
  • OBJECTIVE: To perform a systematic review to evaluate the role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer.
  • CONCLUSIONS: In appropriate patients with gallbladder cancer or cholangiocarcinoma, surgery offers the best chance for survival and should remain the first treatment of choice.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / mortality. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / mortality. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341310.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 18
  •  go-up   go-down


3. Rauws EA: Photodynamic therapy and Klatskin tumour: an overview. Scand J Gastroenterol Suppl; 2006;(243):135-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 60-70% of patients, cholangiocarcinoma is located in the hepatic duct bifurcation and known as Klatskin tumour.
  • Patients with unresectable cholangiocarcinoma are treated with biliary drains, but commonly die of liver failure or cholangitis due to biliary obstruction within 6 to 12 months.
  • In recent non-randomized studies of small numbers of patients with unresectable cholangiocarcinoma, PDT induced a decrease in serum bilirubin levels, improved quality of life and a slightly better survival.
  • Other non-randomized trials failed to show clinical benefits.
  • Recently, the first prospective, randomized controlled study with PDT in a selected group of non-resectable cholangiocarcinoma patients was stopped prematurely.
  • However, further studies are awaited in unselected patients with unresectable cholangiocarcinoma before PDT can be considered as the standard adjuvant therapy.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Hepatic Duct, Common / pathology. Klatskin Tumor / drug therapy. Photochemotherapy
  • [MeSH-minor] Cholangiocarcinoma / drug therapy. Clinical Trials as Topic. Humans

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782632.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 28
  •  go-up   go-down


Advertisement
4. Wada H, Nagano H, Dono K, Kondo M, Yamamoto T, Ota H, Nakamura M, Yoshioka S, Damdinsuren B, Yubo Y, Marubashi S, Miyamoto A, Umeshita K, Nakamori S, Sakon M, Monden M: [Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1711-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
  • The patients of unresectable cholangiocellular carcinoma (CCC) have extremely poor prognosis.
  • FAP hepatic arterial infusion chemotherapy might be promising as an effective therapy for non-resectable CCC without extra hepatic metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / drug therapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage
  • [MeSH-minor] Aged. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Drug Administration Schedule. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Neoplastic Cells, Circulating / drug effects

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553691.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FAP protocol
  •  go-up   go-down


5. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR: Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology; 2000 Sep;32(3):523-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and antitumor effects of TRAIL in human cholangiocarcinoma.
  • In this study, we investigated the expression and therapeutic potential of TRAIL in cholangiocarcinoma, one of the most devastating human hepatic malignancies.
  • Expression of TRAIL receptors was determined in 13 patients with resectable intrahepatic cholangiocarcinoma.
  • Cellular effects of TRAIL in promoting apoptosis of human cholangiocarcinoma cells were analyzed after exposure to recombinant protein, as well as following transfection with a cDNA expression construct.
  • In vivo effects of TRAIL on tumor growth were investigated after subcutaneous injection of cholangiocarcinoma cells into nude mice.
  • Recombinant TRAIL induced extensive programmed cell death in cholangiocarcinoma cell lines lacking decoy receptor expression.
  • Finally, in vivo administration of recombinant TRAIL substantially inhibited subcutaneous tumor growth of human cholangiocarcinoma cells.
  • Induction of apoptosis in tumor cells is possible with a biologically active TRAIL, and suggests that this cytokine is a promising antitumor agent against human cholangiocarcinoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Membrane Glycoproteins / pharmacology. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Amino Acid Sequence / genetics. Animals. Apoptosis / drug effects. Apoptosis Regulatory Proteins. Cell Division / drug effects. Female. Humans. Male. Mice. Mice, Nude. Middle Aged. Molecular Sequence Data. Mutation. Neoplasm Transplantation. Receptors, Tumor Necrosis Factor / metabolism. TNF-Related Apoptosis-Inducing Ligand. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10960444.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-35711
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


6. Nanashima A, Yamaguchi H, Shibasaki S, Ide N, Sawai T, Tsuji T, Hidaka S, Sumida Y, Nakagoe T, Nagayasu T: Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol; 2004 Nov;39(11):1095-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.
  • BACKGROUND: Photodynamic therapy (PDT) is a new palliative option in patients with non-resectable bile duct carcinoma (BDC).
  • METHODS: Five patients had extrahepatic BDC, two had intrahepatic cholangiocarcinoma, and one had ampullary carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / surgery. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm, Residual. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15580404.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


7. Hayashi N, Hasuike Y, Fukuchi N, Kida H, Tujie M, Yoshida T, Ebisui C, Sakita I, Koshino T, Izumiyama K, Koro T, Fujimoto T: [A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1852-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
  • The patient was a 44-year-old man, who was investigated for lateral abdominal pain and liver dysfunction, and subsequently referred to our department with a diagnosis of unresectable intrahepatic cholangiocellular carcinoma (CCC).
  • After 15 courses of home anti-cancer chemotherapy, abdominal CT revealed that the size of intrahepatic metastasis in the left lobe of the liver had not shown growth, whereas other metastitic sites popped up in the caudate lobe, which were free of chemical agent flow.
  • In conclusion, volume reduction surgery followed by transcatheter hepatic arterial chemo infusion might be promising as an effective therapy for non resectable CCC.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Hepatectomy. Humans. Infusions, Intra-Arterial. Liver Neoplasms / secondary. Lymph Node Excision. Male

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315961.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement